Revisión de la estabilidad química del ondansetrón con otros medicamentos en mezclas de administración parenteral

Gabriel Estan-Cerezo; Inmaculada Jiménez-Pulido; Francisco José Rodríguez Lucena; Carmen Matoses Chirivella; Leticia Soriano-Irigaray; Andrés Navarro-Ruiz

doi:10.7399/fh.10787

Revisión de la estabilidad química del ondansetrón con otros medicamentos en mezclas de administración parenteral

Gabriel Estan-Cerezo, Inmaculada Jiménez-Pulido, Francisco José Rodríguez Lucena, Carmen Matoses Chirivella, Leticia Soriano-Irigaray, Andrés Navarro-Ruiz

Resumen

Objetivo: Esta revisión ha sido preparada para recopilar toda la información referente a la estabilidad del ondansetrón en mezclas parenterales junto a otros fármacos.

Método: La búsqueda fue realizada entre septiembre de 2016 y abril de 2017 empleando bases de datos electrónicas como Stabilis® y Micromedex® solutions, Medline/PubMed y Google Académico buscando publicaciones sobre la estabilidad del ondansetrón para infusión vía parenteral cuando es administrado en monoterapia o en una mezcla con otros fármacos.

Resultados: En este trabajo han sido incluidos 49 artículos con un total de 53 fármacos. 15 fármacos han sido descritos como compatibles con ondansetrón en concentraciones habituales en la clínica práctica para administración intravenosa. Además, cuatro mezclas ternarias han sido descritas como compatibles y una como incompatible. Por otro lado, 38 fármacos han sido descritos como incompatibles para su administración con ondansetrón.

Discusión: La compatibilidad del ondansetrón ofrece un amplio rango de opciones para evitar los síntomas de náuseas y vómitos en pacientes con otra medicación concomitante.

Palabras clave

Ondansetrón; Estabilidad; Oncología; Náusea; Medicina paliativa

Texto completo:

PDF (English)

Referencias

Martín de Rosales-Cabrera AM, López-Cabezas C, García-Salom, P. Diseño de una matriz de riesgo para la valoración de los preparados estériles en los centros sanitarios. Farm Hosp. 2014;38(3):202-10.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Open Med. 2009;3(3):e123-30.

Casto DT. Stability of ondansetron stored in polypropylene syringes. Ann Pharmacother. 1994;28(6):712-4.

Bosso JA, Prince RA, Fox JL. Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25°C. Am J Hosp Pharm. 1992;49(9):2223-5.

Blaise N, Vigneron J, Perrin A, Noirez V, Hoffman MA, Hoffman M. Stability of refrigerated and frozen solutions of ondansetron hydrochloride. Eur J Hosp Pharm. 1994;4:12-3.

Graham CL, Dukes GE, Kao CF, Bertch JM, Hak LJ. Stability of ondansetron in largevolume parenteral solutions. Ann Pharmacother. 1992;26(6):768-71.

Jhee SS, Jeong EW, Chin A, Inagaki K, Fox JL, Gill MA. Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4°C. Am J Hosp Pharm. 1993;50(9):1918-20.

Leak RE, Woodford JD. Pharmaceutical development of ondansetron injection. Eur J Cancer Clin Oncol:1989;25 Suppl 1:S67-9.

Stiles ML, Allen LV, Fox JL. Stability of ondansetron hydrochloride in portable infusionpump reservoirs. Am J Health-Syst Pharm. 1992;49(6):1471-3.

Xu QA, Trissel LA, Fox JL. Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration. Ann Pharmacother. 1995;29(11):1106-9.

Chen FC, Zhu J, Li B, Yuan FJ, Wang LH. Stability of tramadol with three 5-HT3 receptor antagonists in polyolefin bags for patient-controlled delivery systems. Drug Des Devel Ther. 2016;10(1):1869-75.

Trissel LA, Xu QA, Martinez JF, Fox JL. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C. Am J Hosp Pharm. 1994;51(17):2138-42.

Altannak NF. Comparative LC-MS stability indicating assays of ondansetron hydrochloride/naloxone hydrochloride and metoclopramide hydrochloride/naloxone hydrochloride used in palliative care. Int J Pharm Pharm Sci. 2015;7(7):109-13.

Hagan RL, Mallett MS, Fox JL. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days. Am J Health-Syst Pharm. 1996;53(12):1431-5.

Evrard B, Ceccato A, Gaspard O, Delattre L, Delporte JP. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection. Am J Health-Syst Pharm. 1997;54(9):1065-8.

Bougouin C, Thelcide C, Crespin-Maillard F, Maillard C, Kinowski JM, Favier M. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers. Am J Health-Syst Pharm. 2005;62(19):2001-5.

Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol. 2013;72(3):509-13.

Fleming RA, Olsen DJ, Savage PD, Fox JL. Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions. Am J Health- Syst Pharm. 1995;52(5):514-6.

Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health-Syst Pharm. 1995;52(22):2570-3.

Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplasic medications. Am J Health-Syst Pharm. 1996;53(11):1297-300.

Estan-Cerezo G, Matoses-Chirivella C, Soriano-Irigaray L, Murcia- López AC, Rodríguez-Lucena FJ, Navarro-Ruiz A. Stability and compatibility of ondansetron with haloperidol in parenteral admixtures. Eur J Hosp Pharm. Published Online First: 13 April 2017. doi: 10.1136/ejhpharm-2016-001200

McGuire TR, Narducci WA, Fox JL. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. Am J Hosp Pharm. 1993;50(7):1410-4.

Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm. 1997;54(8):915-20.

Moya-Gil A, Martínez-Gómez MA, Gras-Colomer E, Porta-Oltra B, limente-Martí M. Stability studies of ternary mixtures containing fosaprepitant, dexamethasone, ondansetron and granisetron used in clinical practice. J Anal Bioanal Tech. 2016;7:307.

Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1991;48(5):988-92.

Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm. 1994;51(14):1792-9.

Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound. 2001;5(4):314-9.

Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm. 1996;53(23):2853-5.

Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound. 2006;10(3):230-2.

Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2004;61(21):2289-93.

Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility ofsargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm. 1992;49(2):402-6.

Fang BX, Li P, Shi XY, Wang LH. Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration. Medicine (Baltimore). 2016;95(25):e3824.

Hauser AR, Trissel LA, Martinez JF. Ondansetron compatible with sodium acetate. J Clin Oncol. 1993;11(1):197.

Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2008;65(16):1545-51.

Summary of product characteristics of Bridion [Accessed April 2017]. Available at https://ec.europa.eu/health/documents/community-register/2016/20160226134295/anx_134295_en.pdf

Mesna and furosemide. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Azathioprine sodium. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Cefepime HCl. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Ondansetron HCl. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Pentobarbital sodium and phenobarbital sodium. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Pantoprazole sodium. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Ertapenem. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Dantrolene sodium. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Foscarnet sodium. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Chloramphenicol sodium succinate. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Cefamandole nafate. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Inamrinone lactate. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Indomethacin sodium. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Trastuzumab. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Rituximab. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

Gemtuzumab. In: Micromedex Solutions [database on the Internet] [Accessed 2017 Mar]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian

DOI: http://dx.doi.org/10.7399%2Ffh.10787